Skip to content
value.today

Prolifagen, Inc.

Total raised
$3 M
1 round on record
Latest round
$3 M
Sep 2025
First round on record
Sep 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Prolifagen, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2025$3 MNo. 1$2 to $10 million

Prolifagen, Inc.: Raise no. 1, Sep 2025

Investors in this round

6 investors had bought by the notice of Sep 23, 2025: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas Alexander Bader · Executive Officer
  • Claudine Bruck · Executive Officer, Director
  • Michael Behr · Executive Officer, Director
  • William Alexander Houston · Executive Officer
  • M. Alexander Shaw · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director, manager or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael Behr, Chief Executive Officer. Newest notice filed Sep 23, 2025. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Prolifagen, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Prolifagen, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Prolifagen, Inc.
NameRoleNamed in
Andreas Alexander BaderExecutive officerSep 2025
Claudine BruckExecutive officerSep 2025
Michael BehrExecutive officerSep 2025
William Alexander HoustonExecutive officerSep 2025
Claudine BruckDirectorSep 2025
M. Alexander ShawDirectorSep 2025
Michael BehrDirectorSep 2025